James McKinnell, MD
Infectious Disease · Torrance, CANPI 1942403035
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $537,441 of the $762,483 with a category attached, or 70.5%. 20 manufacturers reported payments, led by AbbVie at 46.4% of the total. 2025 is the largest year on record at $399,496, 2.4 times the $165,270 reported in 2019. Among infectious disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 923 payments — averaging $826.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$354K
- Aimmune Therapeutics, Inc.$248K
- Remel, Inc.$72K
- AstraZeneca$49K
- Melinta Therapeutics, LLC$12K
- Ferring Pharmaceuticals Inc.$11K
- plus $17K from 14 others
Across 78 payments — averaging $45,936 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.7M
- Genentech, Inc.$1.2M
- Eli Lilly$290K
- AstraZeneca$203K
- Gilead$100K
- Melinta Therapeutics, LLC$59K
- plus $44K from 3 others
What the payments were for
- Consulting fees$137,09118%
- Speaking & faculty fees$537,44170%
- Travel & lodging$70,4679%
- Food & beverage$17,4842%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 562 | $353,641 |
| Aimmune Therapeutics, Inc. | 236 | $247,761 |
| Remel, Inc. | 45 | $72,108 |
| AstraZeneca(2 entities) | 16 | $48,645 |
| Melinta Therapeutics, LLC | 14 | $12,152 |
| Ferring Pharmaceuticals Inc. | 7 | $10,866 |
| Paratek Pharmaceuticals, Inc. | 9 | $5,412 |
| Tetraphase Pharmaceuticals, Inc. | 4 | $4,944 |
| Insmed, Inc. | 4 | $3,265 |
| Pfizer | 1 | $1,400 |
| Shionogi Inc | 3 | $1,201 |
| Accelerate Diagnostics Inc. | 4 | $613 |
| Biomerieux Inc | 3 | $143 |
| Astellas Pharma US Inc | 5 | $92 |
| Merck | 4 | $72 |
| Gilead | 1 | $71 |
| Invivyd Inc | 1 | $36 |
| Mylan Specialty L.p. | 2 | $29 |
| La Jolla Pharmaceutical Company | 1 | $20 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$762,483 in reported general payments places this provider in the 95th percentile of 856 infectious disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CeftriaxoneCeftriaxone Sodium | 15 | $1,454 |
| Cefdinir | 11 | $180 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Torrance
- Behzad NoorianTorrance$120K
- Eric DaarTorrance$72K
- Claire PomeroySacramento$2.6M
- Javeed SiddiquiRoseville$1.5M
- George SakoulasSan Diego$902K
- Arthur JengSylmar$766K
- Jay GladsteinLos Angeles$657K
- Tulika SinghOrange$654K
- Otto YangLos Angeles$472K
- Franco FelizartaBakersfield$440K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.